Eric Venker - 02 Oct 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
Chief Operating Officer
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Issuer symbol
ROIV
Transactions as of
02 Oct 2023
Net transactions value
-$7,900,990
Form type
4
Filing time
04 Oct 2023, 21:30:55 UTC
Previous filing
29 Sep 2023
Next filing
26 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $1,696,895 +440,752 +74% $3.85 1,036,149 02 Oct 2023 Direct
transaction ROIV Common Shares Sale $4,760,122 -440,752 -43% $10.80 595,397 02 Oct 2023 Direct F1
transaction ROIV Common Shares Options Exercise $2,333,951 +606,221 +102% $3.85 1,201,618 03 Oct 2023 Direct
transaction ROIV Common Shares Sale $6,213,765 -606,221 -50% $10.25 595,397 03 Oct 2023 Direct F1
transaction ROIV Common Shares Options Exercise $589,154 +153,027 +26% $3.85 748,424 04 Oct 2023 Direct
transaction ROIV Common Shares Sale $1,547,103 -153,027 -20% $10.11 595,397 05 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -440,752 -3.2% $0.000000 13,382,432 02 Oct 2023 Common Shares 440,752 $3.85 Direct F2
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -606,221 -4.5% $0.000000 12,776,211 03 Oct 2023 Common Shares 606,221 $3.85 Direct F2
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -153,027 -1.2% $0.000000 12,623,184 04 Oct 2023 Common Shares 153,027 $3.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. The Reporting Person's Rule 10b5-1 trading plan does not include any further sales for this calendar year below a sales price of $14.85.
F2 Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).